35 research outputs found
Antibody–Drug Conjugates: The Last Decade
International audienceAn armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of
Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy
International audienc
Evaluation of the anti-<em>Toxoplasma gondi</em>i activity of an inhibitor designed to target CDPK1
National audienc
Domino 6-endo-dig Cyclization/Halogenation Reactions: Three-Component Synthesis of 1,3-Disubstituted 4-Haloimidazo[1,2-a:4,5-c′]dipyridines
International audienc
Conception, synthesis and evaluation of new anti-<em>Toxoplasma gondii</em> agents designed to target CDPK1
National audienc
Conception, synthesis and evaluation of new Toxoplasma gondii inhibitors designed to target CDPK1
National audienc
Conception, synthèse et évaluation de nouveaux inhibiteurs de CDPK1 à visée anti-apicomplexes
National audienc
Imidazo[1,2-b]pyridazines targeting TgCDPK1 as new anti-Toxoplasma gondii chemotherapeutic treatments
Des imidazo[1,2-b]pyridazines ciblant la CDPK1 de <em>Toxoplasma gondii</em> diminuent drastiquement la charge parasitaire dans un modèle de toxoplasmose murine aiguë
National audienc